Drug Trial Radar · NCT06373380
A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7
Actual
Start
Apr 15, 2024
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hookipa Biotech GmbH; Naveris
- First posted
- Apr 18, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers are doing this study to find out if HB-202/HB-201 is a feasible treatment for people with HPV 16-positive head and neck squamous cell cancer (HPV 16+ HNSCC) who have received standard treatment for their disease but then tested positive for HPV 16-related tumor DNA in the blood through a test called NavDx. Participants will have no evidence of cancer on imaging scans (radiographically) or by medical examination (clinically). Past studies have shown that a positive NavDx test strongly suggests the possible presence of microscopic cancer, though we do not know if testing positive will definitely lead to the cancer coming back (recurrence). The NavDx blood test has not been approved by the FDA and is considered investigational.
Conditions
- HPV16+ Squamous Cell Carcinoma
Interventions
HB-200Drug
HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses each of HB-202 and HB-201 alternating).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluable for overall survivalTime frame: up to 3 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New York
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.